Alzheimer's Disease Neuroimaging Initiative 3 (ADNI 3)

Clinical Trial Confidential The major goals of the ADNI3 protocol are to: 1. Determine the relationships among clinical, imaging, genetic, and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s Disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. 2. Inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. 3. Develop improved methods which will lead to uniform standards for acquiring longitudinal multisite MRI and PET data on patients with AD, MCI, and elderly controls. 4. Perform longitudinal clinical, cognitive, MRI, PET (Amyloid, Tau, and FDG), and blood and CSF biomarker studies on newly enrolled subjects in three diagnostic categories – cognitively normal (CN), MCI , and Mild AD. Continue these longitudinal studies for approximately 500 subjects from ADNI2 for an additional 5 years. 5. Collect blood samples for DNA and RNA extraction. Newly enrolled subjects will also have samples collected for Cell Immortalization and APOE genotyping. 6. Validate the clinical diagnoses and imaging and biomarker surrogates through neuropathological examination of subjects who come to autopsy.